| We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. We were founded to solve the problems of post-operative intravenous patient-controlled analgesia (IV PCA). Our lead product, ARX-01, is designed to address IV PCA problems which can cause harm to patients following surgery such as the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. We have three additional product candidates in clinical development: ARX-02 for the treatment of cancer breakthrough pain; ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office; and ARX-04, a non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain. | | |
 |
| 05/08/12 | AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results|
REDWOOD CITY, Calif., May 8, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the first quarter ended March 31, 2012.
Net loss for the first quarter of 2012 was $7.1 million, or $0.36 per share, compared with a net loss of $3.2 million, or $0.30 per share, for... |
|  | | 04/17/12 | AcelRx Pharmaceuticals Announces Hiring of Kim Gaumer as Vice President, Regulatory Affairs and Quality Assurance| REDWOOD CITY, Calif., April 17, 2012 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Kimberley Gaumer to the position of Vice President, Regulatory Affairs and Quality Assurance reporting to Richard King, President and Chief Executive Officer. In this role, Ms. Gaumer will lead all global r... |
| | | 04/12/12 | AcelRx Announces Initiation of Second Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab® PCA System, for the Treatment of Acute Post-Operative Pain| First Subject Dosed in Open-Label, Active-Comparator Trial
REDWOOD CITY, Calif., April 12, 2012 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug Application (NDA) for the... |
| |
|
|
| There are currently no events scheduled. |
Receive E-mail Alerts  | Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
Print Page | 
E-mail Page | 
RSS Feeds